Table 1.
Descriptive statistics of 132 patients who underwent prostate biopsy (PBx) for suspicion of clinical prostate cancer (PCa) with available multiparametric-magnetic resonance imaging (mp-MRI) data.
| Characteristic | Overall n = 132 1 |
Negative PBx n = 56 (42%) 1 |
ISUP Grade Group 1 PCa n = 46 (35%) 1 |
ISUP Grade Group > 1 PCa n = 30 (23%) 1 |
p-Value 2 |
|---|---|---|---|---|---|
| Age (years) | 72 (65, 76) | 68 (61, 75) | 72 (66, 76) | 74 (71, 78) | 0.002 |
| BMI (Kg/m2) | 26.2 (23.9, 28.0) | 26.4 (24.3, 29.0) | 25.9 (23.9, 27.4) | 25.4 (23.9, 28.5) | 0.4 |
| Positive DRE | 57 (44%) | 14 (25%) | 22 (50%) | 21 (70%) | <0.001 |
| PSA (ng/mL) | 7.2 (5.1, 10.0) | 7.0 (5.0, 9.9) | 7.0 (5.3, 10.0) | 8.4 (6.0, 12.0) | 0.2 |
| Prostate volume (ml) | 45 (33, 68) | 58 (43, 84) | 38 (31, 53) | 42 (26, 60) | <0.001 |
| PSA density (ng/mL2) | 0.15 (0.09, 0.25) | 0.11 (0.06, 0.15) | 0.18 (0.08, 0.28) | 0.22 (0.12, 0.50) | <0.001 |
| Number of lesions | 0.9 | ||||
| 1 | 74 (56%) | 32 (57%) | 25 (54%) | 17 (57%) | |
| >1 | 58 (44%) | 24 (43%) | 21 (46%) | 13 (43%) | |
| PIRADS | <0.001 | ||||
| 3 | 33 (25%) | 27 (49%) | 3 (6%) | 3 (10%) | |
| 4 | 58 (44%) | 18 (33%) | 32 (70%) | 8 (27%) | |
| 5 | 40 (31%) | 10 (18%) | 11 (24%) | 19 (63%) | |
| Periprostatic adipose tissue ADC | 876 (654, 1112) | 1003 (773, 1299) | 972 (559, 1103) | 656 (455, 952) | <0.001 |
| Percentage of positive core | 9 (0, 41) | - | 28 (13, 47) | 50 (34, 72) | <0.001 |
| D’Amico risk group | <0.001 | ||||
| Low | 36 (48%) | - | 36 (82%) | 0 (0%) | |
| Intermediate | 28 (38%) | - | 8 (18%) | 20 (67%) | |
| High | 10 (14%) | - | 0 (0%) | 10 (33%) |
1 Median (IQR); n (%). 2 Kruskal–Wallis rank sum test; Pearson’s Chi-square test; Fisher’s exact test; p-values in bold are indicative of statistical significance (<0.05). Abbreviations: ISUP, International Society of Urological Pathology; BMI, Body Mass Index; DRE, digital rectal examination; PSA, prostate-specific antigen; PIRADS, prostate imaging reporting & data system; ADC, apparent diffusion coefficient.